FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GLASSBERG ALAN						2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC [BIIB]									ationship o all applio Directo	,		on(s) to Issi 10% Ow	
(Last) (First) (Middle) 14 CAMBRIDGE CENTER					3. Date of Earliest Transaction (Month/Day/Year) 05/05/2004									Officer below)	(give title		Other (s below)	pecify	
(Street) CAMBRIDGE MA 02142					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									fividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S		(Zip)																
		Tab	ole I - No	n-Deri	vativ	e Se	curit	ties Ac	quired,	Dis	posed o	of, or Be	nefic	ially	Owned				
D				Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		d (A) or r. 3, 4 a	nd 5)	5. Amous Securitie Beneficia Owned F Reported	es Forn ally (D) o Following (I) (Ir		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	e	Transact (Instr. 3	ion(s)			instr. 4)
Common Stock 05/05/2					5/2004	2004			M		30,000) A	\$4.0	0625	5 38,140			D	
Common Stock 05/05/2					5/2004	5/2004					30,000) D	\$	59	8,140			D	
		-	Table II -								osed of, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Yea		е	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amou or Numb of Share	er					
Stock Option (right-to-	\$4.0625	05/05/2004			М			30,000	(2)		02/24/2007	Common Stock	30,0	00	(1)	8,140		D	

Explanation of Responses:

- 1. Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16-3(d).
- 2. Immediately exercisable for all the option shares on 2/24/97 subject to Issuer's repurchase rights which lapse in four (4) equal annual installments.

Remarks:

By: Benjamin S. Harshbarger For: Alan Glassberg

05/06/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

I, the undersigned, a director and/or an executive officer of Biogen Idec Inc., hereby authorize and designate Thomas J. Bucknum, Anne Marie Cook, Jo Ann Taormina, and Benjamin S. Harshbarger and each of them acting alone, as my attorney-in-fact to execute and file on my behalf any and all Forms 3, 4 and 5 (including any amendments thereto) that I may be required to file with the United States Securities and Exchange Commission as a result of my ownership of or transactions in securities of Biogen Idec Inc. The authority granted under this power of attorney shall continue for so long as I am required to file Forms 3, 4 and 5 with regard to my ownership of or transactions in securities of Biogen Idec Inc., unless earlier revoked in writing, but shall terminate automatically as to each individual attorney-in-fact when such person is no longer an employee of Biogen Idec Inc. I acknowledge that the attorneys-in-fact appointed hereunder are not assuming, nor is Biogen Idec Inc. assuming, any of my responsibility to comply with Section 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, the undersigned has caused this instrument to be duly executed this $6 \, \text{th}$ day of February, 2004.

/s/ Alan B. Glassberg

Alan

B. Glassberg